Collaboration and License Agreement - Additional Information (Details) - Bristol-Myers Squibb Company - USD ($)	1 Months Ended		3 Months Ended
	May 31, 2021	Jun. 30, 2020	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	May 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received			$ 50,000,000
Options to License Druggable Target Lesions
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received			31,148,000
Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration term expiration period	42 months
Initial nonrefundable upfront fee received		$ 50,000,000.0
Non-refundable upfront payment received						$ 50,000,000.0
Deferred revenue recognized			400,000		$ 200,000
Revenue Recognized			0	$ 6,500,000	$ 0
Deferred revenue			42,200,000	42,500,000
Deferred revenue, current			2,900,000	2,900,000
Deferred revenue, noncurrent			$ 39,300,000	$ 39,600,000
Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received						301,000,000.0
Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received						176,000,000.0
Collaboration and License Agreement | Maximum | Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received						$ 125,000,000.0